Q2 Earnings Forecast for NeuroPace Issued By Leerink Partnrs

NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Analysts at Leerink Partnrs boosted their Q2 2025 EPS estimates for shares of NeuroPace in a research report issued on Wednesday, June 4th. Leerink Partnrs analyst M. Kratky now expects that the company will post earnings of ($0.22) per share for the quarter, up from their prior forecast of ($0.23). The consensus estimate for NeuroPace's current full-year earnings is ($1.00) per share. Leerink Partnrs also issued estimates for NeuroPace's Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.83) EPS, FY2026 earnings at ($0.40) EPS, FY2027 earnings at ($0.18) EPS, FY2028 earnings at $0.14 EPS and FY2029 earnings at $0.46 EPS.

NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.05. The company had revenue of $22.52 million for the quarter, compared to analyst estimates of $21.85 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%.

A number of other research analysts have also issued reports on the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $17.00 target price on shares of NeuroPace in a report on Wednesday, May 14th. HC Wainwright began coverage on shares of NeuroPace in a research note on Wednesday, May 28th. They issued a "buy" rating and a $18.00 price objective on the stock. Finally, JPMorgan Chase & Co. boosted their price objective on shares of NeuroPace from $14.00 to $16.00 and gave the company an "overweight" rating in a research note on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $15.50.

NeuroPace Stock Performance

Shares of NPCE stock opened at $13.15 on Monday. The stock has a market capitalization of $431.31 million, a PE ratio of -13.15 and a beta of 2.03. NeuroPace has a 52-week low of $5.45 and a 52-week high of $18.98. The stock's 50-day moving average price is $12.91 and its 200 day moving average price is $12.35. The company has a quick ratio of 4.77, a current ratio of 5.59 and a debt-to-equity ratio of 6.03.

Insider Buying and Selling

In other news, major shareholder Orbimed Advisors Llc sold 168,136 shares of the stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $15.85, for a total value of $2,664,955.60. Following the completion of the transaction, the insider now owns 3,238,199 shares in the company, valued at $51,325,454.15. This trade represents a 4.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 22.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in NPCE. Financial Advocates Investment Management grew its holdings in shares of NeuroPace by 27.8% in the 4th quarter. Financial Advocates Investment Management now owns 23,000 shares of the company's stock worth $257,000 after acquiring an additional 5,000 shares during the period. Palumbo Wealth Management LLC acquired a new stake in NeuroPace in the fourth quarter valued at $129,000. Bank of New York Mellon Corp grew its holdings in NeuroPace by 21.2% in the fourth quarter. Bank of New York Mellon Corp now owns 29,342 shares of the company's stock valued at $328,000 after purchasing an additional 5,133 shares during the last quarter. JPMorgan Chase & Co. grew its stake in NeuroPace by 440.4% in the 4th quarter. JPMorgan Chase & Co. now owns 64,826 shares of the company's stock valued at $725,000 after acquiring an additional 52,829 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of NeuroPace by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 322,973 shares of the company's stock valued at $3,615,000 after purchasing an additional 5,781 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.